Maryland 2024 Regular Session

Maryland House Bill HB986

Introduced
2/5/24  
Refer
2/5/24  
Report Pass
4/3/24  
Engrossed
4/3/24  
Refer
4/3/24  
Refer
4/5/24  
Report Pass
4/6/24  
Enrolled
4/8/24  
Chaptered
5/16/24  

Caption

Maryland Medical Assistance Program - Coverage for the Treatment of Obesity - Required Study

Impact

The findings from the study mandated by HB 986 could significantly influence healthcare policies in Maryland. By evaluating existing treatment coverage under medical assistance programs in other states, the Department of Health will assess the benefits and challenges of expanding coverage for obesity treatments. If the coverage is adopted, it could lead to a marked shift in how obesity is treated within the Medicaid framework, potentially improving access to necessary medical interventions for low-income residents who struggle with obesity.

Summary

House Bill 986 requires the Maryland Department of Health to study the implications of mandating comprehensive coverage for the treatment of obesity under the Maryland Medical Assistance Program. This legislation aims to explore the feasibility and potential cost savings of offering such coverage, which would encompass intensive behavioral therapy, bariatric surgery, and FDA-approved antiobesity medications. The bill emphasizes the growing recognition of obesity as a chronic disease that necessitates effective management strategies through healthcare coverage.

Sentiment

General sentiment around the bill appears to be positive, with broad support for enhancing healthcare coverage for obesity treatment. Advocates argue that comprehensive coverage would not only benefit individuals suffering from obesity but could also result in long-term healthcare savings by preventing weight-related health issues. However, there may be concerns regarding the costs associated with such an expansion of coverage, and whether the state budget can accommodate these changes sustainably.

Contention

Notably, the bill stipulates criteria surrounding the coverage of FDA-approved antiobesity medications, emphasizing that access shall not be more restrictive than the drug's indicated use. This could raise questions about the balance between healthcare cost control and providing adequate care for patients. Also, as the study is conducted over the coming years, stakeholders may debate the proposed timelines and implementation steps, especially in comparison to the growing public health challenge posed by obesity.

Companion Bills

MD SB594

Crossfiled Maryland Medical Assistance Program - Coverage for the Treatment of Obesity - Required Study

Similar Bills

MD SB594

Maryland Medical Assistance Program - Coverage for the Treatment of Obesity - Required Study

MD HB1048

Behavioral Health Advisory Council and Commission on Behavioral Health Care Treatment and Access - Alterations

MD SB212

Behavioral Health Advisory Council and Commission on Behavioral Health Care Treatment and Access - Alterations

MD SB460

Maryland Medical Assistance Program – Gender–Affirming Treatment (Trans Health Equity Act)

MD HB283

Maryland Medical Assistance Program - Gender-Affirming Treatment (Trans Health Equity Act)

MD HB1489

Maryland Medical Assistance Program - Coverage for the Treatment of Obesity

MD HB1059

Health - Maryland Helping Everyone Afford Life-Saving Treatments and Health Care (HEALTH) Fund and Income Tax Checkoff

MD SB974

Maryland Medical Assistance Program and Health Insurance - Nonopioid Drugs for the Treatment of Pain